American Century Companies
KNTE

American Century Companies’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

American Century Companies’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,906
Closed -$20.9K – 2941
2023
Q3 		$20.9K Buy
+14,906
New +$35.8K ﹤0.01% 2835
2023
Q1 		– Sell
-322,030
Closed -$1.96M – 2707
2022
Q4 		$1.96M Buy
322,030
+196
+0.1% +$1.6K ﹤0.01% 1553
2022
Q3 		$3.85M Buy
321,834
+1,879
+0.6% +$24.6K ﹤0.01% 1208
2022
Q2 		$4.04M Buy
319,955
+428
+0.1% +$3.98K ﹤0.01% 1183
2022
Q1 		$3.6M Buy
319,527
+105,882
+50% +$1.17M ﹤0.01% 1212
2021
Q4 		$3.79M Buy
213,645
+39,855
+23% +$840K ﹤0.01% 1144
2021
Q3 		$4M Buy
173,790
+71
+0% +$1.55K ﹤0.01% 1090
2021
Q2 		$4.04M Buy
173,719
+248
+0.1% +$6.31K ﹤0.01% 1044
2021
Q1 		$5.41M Buy
173,471
+166,336
+2,331% +$5.8M ﹤0.01% 919
2020
Q4 		$284K Buy
+7,135
New +$286K ﹤0.01% 1751

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies's KNTE Position: Q4 2023 in Review

American Century Companies sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 14,906 shares — an estimated $20.9K sold.

American Century Companies first reported a position in KNTE in Q4 2020 and held it in 10 quarters. The position peaked at $5.41M in Q1 2021. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • American Century Companies reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • American Century Companies sold 14,906 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $20.9K.
  • American Century Companies first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • American Century Companies's Kinnate Biopharma Inc. Common Stock position peaked at $5.41M in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on American Century Companies's 13F filing for Q4 2023, filed 13 Feb 2024.